Product Description
V-419 is being developed by Sanofi for the treatment of Neisseria Meningitidis, Bacterial Infections, and Virus Diseases. (Sourced from: https://clinicaltrials.gov/ct2/show/NCT01553279?term=V-419&draw=2&rank=1)
Mechanisms of Action: Vaccine
Novel Mechanism: No
Modality: Vaccine
Route of Administration: Intramuscular
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: MCM Vaccines B.V.
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 4: Healthy Volunteers|Diphtheria|Tetanus|Poliomyelitis|Anus Diseases|Influenza, Human|Hepatitis B
Phase 3: Hepatitis A|Hepatitis B|Diphtheria|Tetanus|Influenza, Human|Poliomyelitis|Whooping Cough|Anus Diseases
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| V419-016 | P4 |
Completed |
Healthy Volunteers |
2022-08-30 |
|
| 2021-004053-23 | P4 |
Active, not recruiting |
Hepatitis B|Influenza, Human|Diphtheria|Anus Diseases|Tetanus|Poliomyelitis |
2022-05-14 |
|
| A Hepatitis B Vaccine Challenge Study After Previous Vaxelis® Vaccination | P3 |
Completed |
Hepatitis B |
2021-03-08 |
|
| 2016-000274-37 | P3 |
Completed |
Anus Diseases|Tetanus|Influenza, Human|Diphtheria|Poliomyelitis|Hepatitis B |
2017-04-05 |